Presentation is loading. Please wait.

Presentation is loading. Please wait.

Rudy Dekeyser 21/04/05 _Rotterdam 21/04/05.

Published byBrian O'Neil Modified over 10 years ago

Similar presentations

Presentation on theme: "Rudy Dekeyser 21/04/05 _Rotterdam 21/04/05."— Presentation transcript:

1 Rudy Dekeyser 21/04/05 _Rotterdam 21/04/05

2 origin of the species mission & objectives
creating an innovative environment is basic high quality research compatible with tech transfer? _Rotterdam 21/04/05

3 origin of the species mission & objectives
creating an innovative environment is basic high quality research compatible with tech transfer? _Rotterdam 21/04/05

4 Origin of the species Antwerp Diepenbeek Ghent Louvain Brussels
_Rotterdam 21/04/05

5 Origin of the species Step 1. Flemish government evaluates the life sciences research [1994] _Rotterdam 21/04/05

6 Origin of the species The 1994 conclusions: big names in science
but lack of structural support critical mass translation in industrial activities _Rotterdam 21/04/05

7 Origin of the species The conventional approach:
Dedicate a certain volume of an existing granting body to life sciences research danger: slice it thin lack of sustainability Establish a novel independent research institution danger: disturb the equilibrium lag phase _Rotterdam 21/04/05

8 Origin of the species Step 2. The VIB concept unite existing quality
build synergy and critical mass research tech transfer _Rotterdam 21/04/05

9 Origin of the species VIB – unite existing quality
60 biotech teams in 5 universities evaluation select 9 excellent teams _Rotterdam 21/04/05

10 Origin of the species U1 U2 U3 VIB vzw U4 U5 _Rotterdam 21/04/05

11 Origin of the species VIB – create critical mass
Flemish government invests 5y x 25M€ = € = doubling research budget overnight = creating critical mass Framework agreement: long term commitment in depth evaluation every 5 year _Rotterdam 21/04/05

12 Origin of the species VIB – create synergy
Framework agreement with universities key output: scientific publications 752 / October 2004 / volume 5 _Rotterdam 21/04/05

13 Origin of the species VIB – create synergy
Framework agreement with universities tech transfer: IPR joint ownership management: VIB costs: VIB marketing/exploitation: VIB _Rotterdam 21/04/05

14 Origin of the species VIB – create synergy
Framework agreement with universities tech transfer - return € € € patent cost inventors VIB 50 univ 50 VIB 40 40 10 10 Department _Rotterdam 21/04/05

15 Origin of the species VIB – create synergy
Framework agreement with universities tech transfer – return UNIV : = 90% VIB : = 90% _Rotterdam 21/04/05

16 Origin of the species VIB – key facts & figures foundation : 1996
legal entity : not-for-profit field : life sciences budget 2004 : ~ 60 mio € headcount : ~ 850 _Rotterdam 21/04/05

17 origin of the species mission & objectives
creating an innovative environment is basic high quality research compatible with tech transfer? _Rotterdam 21/04/05

18 Molecular sciences to improve the quality of life
Mission Molecular sciences to improve the quality of life _Rotterdam 21/04/05

19 Objectives conduct frontline basic research
translate inventions into products for the benefit of society inform the public _Rotterdam 21/04/05

20 origin of the species mission & objectives
creating an innovative environment is basic high quality research compatible with tech transfer? _Rotterdam 21/04/05

21 VIB - Research Major fields: Oncology Cardiovascular/angiogenesis
Neurobiology Inflammation/immunology Developmental biology Plant system biology Microbiology _Rotterdam 21/04/05

22 VIB - Research apoptosis inflammation TNF membrane TNF-R55 TNF-R75
TRADD ABIN A20 Ub TRAF2 RIP IKK FADD Ub Ub IKK/  IKK / casp8 P P MAP3K P apoptosis P Ub P IB P IB p50 p65 p50 p65 nucleus NF-B dependent genes inflammation p50 p65 _Rotterdam 21/04/05

23 VIB - Research Novel treatment for IBD in clinical trial
Recombinant L.lactis, expressing IL-10 Colitis ulcerosa Crohn’s disease healthy colon _Rotterdam 21/04/05

24 VIB - Research VEGF promoter polymorphisms reduce VEGF expression
VEGF d/d mice show adult onset ALS phenotype Reduced levels of VEGF increase the risk for ALS _Rotterdam 21/04/05

25 VIB - Research Quantitative N-teromics
Arg N Arc C 18O Ex.: Heatmap of ratios of amino-terminal peptides for 700 IDs from T-Lymphocyte According to reverse phase chromatography position According to ratio (O18/O16) _Rotterdam 21/04/05

26 VIB - Research _Rotterdam 21/04/05

27 VIB – Tech Transfer Tech Transfer = Technology Transfer
= Knowledge Transfer = the movement of knowledge between different parties = the transfer of knowledge from an academic institution to industry = patenting, licensing and establishing start-ups = mining of knowledge => optimize knowledge creation _Rotterdam 21/04/05

28 VIB - Research Target : frontline Create the environment:
recognise excellence top performance => budget low performance => budget excellence bonus recruit internationally _Rotterdam 21/04/05

29 international recognition
VIB – Research international recognition 39 nationalities 58% European countries 23 % Asia 11% N&S America 6,5 % Africa 1% Australia % internationalisation _Rotterdam 21/04/05

30 VIB - Research Target : frontline Create the environment:
recognise excellence up to date infrastructure _Rotterdam 21/04/05

31 UGent-VIB research building
_Rotterdam 21/04/05

32 _Rotterdam 21/04/05

33 VIB - Research Target : frontline Create the environment:
recognise excellence up to date infrastructure access to advanced technology platforms _Rotterdam 21/04/05

34 VIB microarray facility
_Rotterdam 21/04/05

35 VIB proteomics core facility
(Source: PhD thesis Kris Gevaert, 2000) _Rotterdam 21/04/05

36 VIB Genetic Service Facility
sequencing STR-genotyping SNP discovery SNP analysis _Rotterdam 21/04/05

37 VIB technology – model organisms
yeast drosophila zebrafish xenopus mouse arabidopsis _Rotterdam 21/04/05

38 VIB technologies Bio-informatics _Rotterdam 21/04/05

39 VIB - Research Target : frontline Create the environment:
Stimulate debate and interaction GLC VIB seminar VIB newsletter science clubs PhD program _Rotterdam 21/04/05

40 VIB - Research Quality assurance: IAB _Rotterdam 21/04/05

41 Institutional Advisory Board 2004
_Rotterdam 21/04/05

42 VIB - Research Quality assurance IAB SAB strategic plan
organigram [critical density] _Rotterdam 21/04/05

43 VIB - Research _Rotterdam 21/04/05

44 VIB - Research Quality assurance IAB SAB strategic plan organigram
performance criteria _Rotterdam 21/04/05

45 VIB - Research Performance criteria: scientifically
≥ 45 publications in IF > 10 journals ≥ 125 publications in IF > 5 journals tech transfer ≥ 25 patent applications 50% granted ≥ 5 mio € industry funding education ≥ 35 PhD’s _Rotterdam 21/04/05

46 VIB - Research IF > 5 IF > 10 X 2.7 X 3.3 _Rotterdam 21/04/05

47 agreements existing companies
VIB – Tech Transfer research agreements existing companies records of invention IPR start-ups facilitate the commercialisation of research results for the benefit of society promote economic growth job creation generate research € to dept. _Rotterdam 21/04/05

48 VIB – Tech Transfer Disclosure and recording of inventions Policy:
adapt to academic environment pro-active minimize administrative hurdles treat with priority _Rotterdam 21/04/05

49 VIB - Tech Transfer Inventions _Rotterdam 21/04/05

50 VIB - Tech Transfer M €/ROI ROI-benchmark 3 2,5 2 1,5 1 0,5 V IB
V IB M €/ROI Can. Inst. US Inst. US Univ. Cal Tech ARCH Stanford _Rotterdam 21/04/05

51 VIB - Tech Transfer # patent applications _Rotterdam 21/04/05

52 VIB - Tech Transfer Patent applications (PA) VIB : ~ 48% ROI => PA
Benchmark : ~ 50% ROI => PA _Rotterdam 21/04/05

53 VIB – Tech Transfer portfolio management Priority filing EU US UK
PCT filing National phase Granting 2nd filing Search report Written opinion Preliminary Examination Report _Rotterdam 21/04/05

54 Budgets/year - cumulative
VIB – Tech Transfer Budgets/year - cumulative _Rotterdam 21/04/05

55 VIB - Tech Transfer Licensing/R&D: some collaborators Pfizer
Novartis Johnson & Johnson Solvay Abbott Bayer Innogenetics Tibotec Galapagos CropDesign Ablynx Tigenix _Rotterdam 21/04/05

56 VIB - Tech Transfer Start-up: basic principles
VIB operates in a very hands-on manner by playing the role of seed financier: conceptualize and write business plan strengthen the technology/product base via inlicensing assist in bringing the team in place road show to raise venture money assist in the due diligence process _Rotterdam 21/04/05

57 VIB - Tech Transfer Start-up: case study - nanobody
Broad application spectrum diagnostics/proteomics therapeutics immuno-affinity feed/food _Rotterdam 21/04/05

58 VIB - Tech Transfer Start-up: case study – nanobody
Technology building secured access to 3 basic patents covering product claims and production methodology (VUB) filed 6 more patent families > 40 patent applications and patents (2) Strategic investments: VIB grant complemented with: tech transfer project IWT grant _Rotterdam 21/04/05

59 VIB - Tech Transfer Start-up: case study – nanobody
(3) Business plan (Ablynx) (4) Attract lead investor (GIMV) (5) Establish legal entity (VIB + GIMV) (6) Attract CEO (M. Vaeck, ex-COO Ceres) (7) Ad interim management recruit first employees rent lab space furnish labs establish contacts with potential licensees _Rotterdam 21/04/05

60 Ablynx nv Biopharma Foundation : 2001 Location : Ghent
CEO : Dr. Mark Vaeck Venture Capital 1st round : 5 M € Investors : GIMV, BFV, Sofinnova, Gilde Venture Capital 2nd round : 25 M € New investors : Abingworth, Alta Partners Employees : 40 _Rotterdam 21/04/05

61 Devgen nv Biopharma & agbio Foundation : 1997 Location : Ghent
CEO : Dr. Thierry Bogaert Venture Capital 1st round : 9.4 M € Investors 1st round : GIMV, Abingworth, BVF Venture Capital 2nd round : M € New investors : Advent, LSP, Rendex, ING, DV, KBC, M&M Employees : 95 _Rotterdam 21/04/05

62 CropDesign nv Agbio Foundation : 1998 Location : Ghent
CEO: : Dr. Johan Cardoen Venture Capital 1st round : 11 M USD Investors 1st round : GIMV, Atlas Venture, Sofinnova, BFF Venture Capital 2nd round : M € New Investors : Gilde, ING, DV, Burrill Agbio, KBC, Technolife 2010 Venture Capital 3th round : 16 M€ Employees : 70 _Rotterdam 21/04/05

63 Peakadilly nv Biopharma Foundation : 2004 Location : Ghent
CEO : Koen Kas Capital 1st round : VIB Income : 3 mio € Employees : 10 _Rotterdam 21/04/05

64 Tech Transfer Start-ups: employees _Rotterdam 21/04/05

65 VIB start-up Benefit for society:
multiple therapeutics under development novel agronomically improved crop varieties under deveopment _Rotterdam 21/04/05

66 VIB - Tech Transfer _Rotterdam 21/04/05

67 Service Center for biotech
Ghent Technology Park DeVGen Innogenetics DeVGen VIB Bio-incubator 2 research facilities University of Ghent/VIB Bayer Bio Science VIB Bio-incubator 1 Innovation& Incubation centre 2 (University of Ghent) Innovation & Incubation centre 1 (University of Gent) Crop Design Service Center for biotech Buildings planned or under construction _Rotterdam 21/04/05

68 _Rotterdam 21/04/05

69 Conclusion scientific output and quality improved significantly
tech transfer output has increased from almost zero to significant _Rotterdam 21/04/05

70 origin of the species mission & objectives
creating an innovative environment is basic high quality research compatible with tech transfer? _Rotterdam 21/04/05

71 Balancing science & Tech Transfer
Groups with collaboration Groups without collaboration Yearly avg # pubs science technology basic applied Source: K. Debackere et al., in prep. _Rotterdam 21/04/05

72 Balancing science & Tech Transfer
Table 1a – average number of SCIE publications ( ) Inventors Non-inventors Complete sample 35,8 11,7 Sample without outliers (# pubs < 90) 22,8 12,1 Source: K. Debackere et al., in prep. _Rotterdam 21/04/05

73 Balancing science & Tech Transfer
Conclusion: High quality basic science & tech transfer are compatible _Rotterdam 21/04/05

Download ppt "Rudy Dekeyser 21/04/05 _Rotterdam 21/04/05."

Similar presentations

Go-to-Market Strategy

Go-to-Market Strategy
Technology Commercialisation System Richard Linley Associate Consultant.

Technology Commercialisation System Richard Linley Associate Consultant.
HART RESEARCH P e t e r D A S O T E C I Raising The Bar

HART RESEARCH P e t e r D A S O T E C I Raising The Bar
1 ABOUT THE INSTITUTE ABOUT THE INSTITUTE SOFIA UNIVERSITY ST. KLIMENT OHRIDSKI, BULGARIA CENTRE FOR EUROPEAN RESEARCH, TRAINING AND DEVELOPMENT PROGRAMMES.

1 ABOUT THE INSTITUTE ABOUT THE INSTITUTE SOFIA UNIVERSITY ST. KLIMENT OHRIDSKI, BULGARIA CENTRE FOR EUROPEAN RESEARCH, TRAINING AND DEVELOPMENT PROGRAMMES.
Yrjö Neuvo EIT Governing Board The EIT Sustainable Growth and Competitiveness through Innovation.

Yrjö Neuvo EIT Governing Board The EIT Sustainable Growth and Competitiveness through Innovation.
European Economic and Social Committee Consultative Committee on Industrial Change CCMI P r e s e n t a t i o n of J á n o s T Ó T H Member of the EESC.

European Economic and Social Committee Consultative Committee on Industrial Change "CCMI" P r e s e n t a t i o n of J á n o s T Ó T H Member of the EESC.
1 Learning for employment vocational education and training policy in Europe in Europe.

1 Learning for employment vocational education and training policy in Europe in Europe.
Johan Carlsten Vice-President Chalmers University of Technology Chalmers School of Entrepreneurship - Accelerating research commercialization.

Johan Carlsten Vice-President Chalmers University of Technology Chalmers School of Entrepreneurship - Accelerating research commercialization.
Life Science Cluster in Krakow

Life Science Cluster in Krakow
Promoting Innovation in the German Capital Region

Promoting Innovation in the German Capital Region
DEVELOPMENT OF AN INNOVATION CENTER WIPO/INN/MCT/04/3 WIPO NATIONAL WORKSHOP ON INNOVATION SUPPORT SERVICES AND THEIR MANAGEMENT Muscat, April 20, 2004.

DEVELOPMENT OF AN INNOVATION CENTER WIPO/INN/MCT/04/3 WIPO NATIONAL WORKSHOP ON INNOVATION SUPPORT SERVICES AND THEIR MANAGEMENT Muscat, April 20, 2004.
Developing an International Perspective: Using the PCT Jay Erstling Director, Office of the PCT World Intellectual Property Organization (WIPO) Geneva,

Developing an International Perspective: Using the PCT Jay Erstling Director, Office of the PCT World Intellectual Property Organization (WIPO) Geneva,
IP MANAGEMENT IN UNIVERSITIES

IP MANAGEMENT IN UNIVERSITIES
Biosciences Innovation Policy Consortium for Eastern Africa (BIPCEA) Towards a Bio-economy in Eastern Africa Julius Ecuru 29/9/11 Kampala, Uganda.

Biosciences Innovation Policy Consortium for Eastern Africa (BIPCEA) Towards a Bio-economy in Eastern Africa Julius Ecuru 29/9/11 Kampala, Uganda.
Creation of Pilot IP Fund Liis Käosaar-Sasi Dorel Tamm.

Creation of Pilot IP Fund Liis Käosaar-Sasi Dorel Tamm.
How to succesfully obtain a Valorisation Grant October 11 th, 2012 Stefan Jongerius Wouter Segeth.

How to succesfully obtain a Valorisation Grant October 11 th, 2012 Stefan Jongerius Wouter Segeth.
Manchester Science Enterprise Centre Intellectual Property Dr Robert A. Phillips Manchester Science Enterprise Centre.

Manchester Science Enterprise Centre Intellectual Property Dr Robert A. Phillips Manchester Science Enterprise Centre.
UK and Rwanda Trade & Investment Forum 22 nd October 2014 Confidential Changing the Game for Africa.

UK and Rwanda Trade & Investment Forum 22 nd October 2014 Confidential Changing the Game for Africa.
Martin Schuurmans Chair EIT The EIT Sustainable Growth and Competitiveness through Innovation.

Martin Schuurmans Chair EIT The EIT Sustainable Growth and Competitiveness through Innovation.
Grant Information Search Dr. E. K. Ingbian Associate professor ( Department of Food Science and Technology ) Directorate of Research and Development University.

Grant Information Search Dr. E. K. Ingbian Associate professor ( Department of Food Science and Technology ) Directorate of Research and Development University.

Similar presentations

Ads by Google